You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study

Citation Tools

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Verschraegen CF, Jerusalem G, McClay EF, et al
Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study
Journal for ImmunoTherapy of Cancer 2020;8:e001064. doi: 10.1136/jitc-2020-001064